nach oben

Clinical Reviews in Allergy & Immunology

Erschienen in:

25.08.2018

Contact Dermatitis to Medications and Skin Products

verfasst von: Henry L. Nguyen, James A. Yiannias

Erschienen in: Clinical Reviews in Allergy & Immunology | Ausgabe 1/2019

Einloggen, um Zugang zu erhalten

Abstract

Consumer products and topical medications today contain many allergens that can cause a reaction on the skin known as allergic contact dermatitis. This review looks at various allergens in these products and reports current allergic contact dermatitis incidence and trends in North America, Europe, and Asia. First, medication contact allergy to corticosteroids will be discussed along with its five structural classes (A, B, C, D1, D2) and their steroid test compounds (tixocortol-21-pivalate, triamcinolone acetonide, budesonide, clobetasol-17-propionate, hydrocortisone-17-butyrate). Cross-reactivities between the steroid classes will also be examined. Next, estrogen and testosterone transdermal therapeutic systems, local anesthetic (benzocaine, lidocaine, pramoxine, dyclonine) antihistamines (piperazine, ethanolamine, propylamine, phenothiazine, piperidine, and pyrrolidine), topical antibiotics (neomycin, spectinomycin, bacitracin, mupirocin), and sunscreen are evaluated for their potential to cause contact dermatitis and cross-reactivities. Finally, we examine the ingredients in the excipients of these products, such as the formaldehyde releasers (quaternium-15, 2-bromo-2-nitropropane-1,3 diol, diazolidinyl urea, imidazolidinyl urea, DMDM hydantoin), the non-formaldehyde releasers (isothiazolinones, parabens, methyldibromo glutaronitrile, iodopropynyl butylcarbamate, and thimerosal), fragrance mixes, and Myroxylon pereirae (Balsam of Peru) for contact allergy incidence and prevalence. Furthermore, strategies, recommendations, and two online tools (SkinSAFE and the Contact Allergen Management Program) on how to avoid these allergens in commercial skin care products will be discussed at the end.

Diepgen TL, Ofenloch RF, Bruze M, Bertuccio P, Cazzaniga S, Coenraads PJ, Elsner P, Goncalo M, Svensson Å, Naldi L (2016) Prevalence of contact allergy in the general population in different European regions. Br J Dermatol 174(2):319–329CrossRefPubMed

Thyssen JP, Linneberg A, Menné T, Johansen JD (2007) The epidemiology of contact allergy in the general population—prevalence and main findings. Contact Dermatitis 57(5):287–299CrossRefPubMed

Nielsen NH, Menne T (1992) Allergic contact sensitization in an unselected Danish population. The Glostrup Allergy Study, Denmark. Acta Derm Venereol 72(6):456–460PubMed

Nielsen NH, Linneberg A, Menne T et al (2001) Allergic contact sensitization in an adult Danish population: two cross-sectional surveys eight years apart (the Copenhagen Allergy Study). Acta Derm Venereol 81(1):31–34CrossRefPubMed

Thyssen JP, Linneberg A, Menne T, Nielsen NH, Johansen JD (2009) Contact allergy to allergens of the TRUE-test (panels 1 and 2) has decreased modestly in the general population. Br J Dermatol 161(5):1124–1129CrossRefPubMed

Schafer T, Bohler E, Ruhdorfer S et al (2001) Epidemiology of contact allergy in adults. Allergy 56(12):1192–1196CrossRefPubMed

Dotterud LK, Smith-Sivertsen T (2007) Allergic contact sensitization in the general adult population: a population-based study from Northern Norway. Contact Dermatitis 56(1):10–15CrossRefPubMed

Mortz CG, Lauritsen JM, Bindslev-Jensen C, Andersen KE (2002) Contact allergy and allergic contact dermatitis in adolescents: prevalence measures and associations. The Odense Adolescence Cohort Study on Atopic Diseases and Dermatitis (TOACS). Acta Derm Venereol 82(5):352–358CrossRefPubMed

Nielsen NH, Linneberg A, Menne T et al (2002) Incidence of allergic contact sensitization in Danish adults between 1990 and 1998; the Copenhagen Allergy Study, Denmark. Br J Dermatol 147(3):487–492CrossRefPubMed

10.

Lim HW, Collins SAB, Resneck JS Jr, Bolognia JL, Hodge JA, Rohrer TA, van Beek MJ, Margolis DJ, Sober AJ, Weinstock MA, Nerenz DR, Smith Begolka W, Moyano JV (2017) The burden of skin disease in the United States. J Am Acad Dermatol 76(5):958–972 e952CrossRefPubMed

11.

Clark SC, Zirwas MJ (2009) Management of occupational dermatitis. Dermatol Clin 27(3):365–383 vii–viiiCrossRefPubMed

12.

Schwindt DA, Wilhelm KP, Miller DL, Maibach HI (1998) Cumulative irritation in older and younger skin: a comparison. Acta Derm Venereol 78(4):279–283CrossRefPubMed

13.

Thyssen JP, Johansen JD, Linneberg A, Menne T (2010) The epidemiology of hand eczema in the general population—prevalence and main findings. Contact Dermatitis 62(2):75–87CrossRefPubMed

14.

Jakasa I, Verberk MM, Esposito M, Bos JD, Kezic S (2007) Altered penetration of polyethylene glycols into uninvolved skin of atopic dermatitis patients. J Invest Dermatol 127(1):129–134CrossRefPubMed

15.

Lerbaek A, Kyvik KO, Mortensen J, Bryld LE, Menne T, Agner T (2007) Heritability of hand eczema is not explained by comorbidity with atopic dermatitis. J Invest Dermatol 127(7):1632–1640CrossRefPubMed

16.

Gibson-Smith B, Fleming CJ, Forsyth A (1998) Contact sensitivity to tixocortol pivalate in sisters. Contact Dermatitis 38(6):351–352CrossRefPubMed

17.

Warshaw EM, Hagen SL, DeKoven JG et al (2017) Occupational contact dermatitis in North American production workers referred for patch testing: retrospective analysis of cross-sectional data from the North American Contact Dermatitis Group 1998 to 2014. Dermatitis 28(3):183–194CrossRefPubMed

18.

King TC (2007) 2—inflammation, inflammatory mediators, and immune-mediated disease. In: Elsevier’s integrated pathology. Mosby, Philadelphia, pp 21–57CrossRef

19.

Friedmann PS (2007) The relationships between exposure dose and response in induction and elicitation of contact hypersensitivity in humans. Br J Dermatol 157(6):1093–1102CrossRefPubMed

20.

Nguyen SH, Dang TP, MacPherson C, Maibach H, Maibach HI (2008) Prevalence of patch test results from 1970 to 2002 in a multi-centre population in North America (NACDG). Contact Dermatitis 58(2):101–106CrossRefPubMed

21.

Lunder T, Kansky A (2000) Increase in contact allergy to fragrances: patch-test results 1989–1998. Contact Dermatitis 43(2):107–109CrossRefPubMed

22.

Mortz CG, Bindslev-Jensen C, Andersen KE (2013) Prevalence, incidence rates and persistence of contact allergy and allergic contact dermatitis in the Odense Adolescence Cohort Study: a 15-year follow-up. Br J Dermatol 168(2):318–325CrossRefPubMed

23.

Peiser M, Tralau T, Heidler J, Api AM, Arts JHE, Basketter DA, English J, Diepgen TL, Fuhlbrigge RC, Gaspari AA, Johansen JD, Karlberg AT, Kimber I, Lepoittevin JP, Liebsch M, Maibach HI, Martin SF, Merk HF, Platzek T, Rustemeyer T, Schnuch A, Vandebriel RJ, White IR, Luch A (2012) Allergic contact dermatitis: epidemiology, molecular mechanisms, in vitro methods and regulatory aspects. Current knowledge assembled at an international workshop at BfR, Germany. Cell Mol Life Sci 69(5):763–781CrossRefPubMed

24.

Pongpairoj K, Puangpet P, Thaiwat S, McFadden JP (2017) Diagnosing allergic contact dermatitis through elimination, Perception, Detection and Deduction. Am J Clin Dermatol

25.

Burckhardt W (1959) Contact eczema caused by hydrocortisone. Hautarzt 10:42–43PubMed

26.

Wilkinson SM, Jones MF (1996) Corticosteroid usage and binding to arginine: determinants of corticosteroid hypersensitivity. Br J Dermatol 135(2):225–230CrossRefPubMed

27.

Baeck M, Marot L, Nicolas JF, Pilette C, Tennstedt D, Goossens A (2009) Allergic hypersensitivity to topical and systemic corticosteroids: a review. Allergy 64(7):978–994CrossRefPubMed

28.

Coopman S, Degreef H, Dooms-Goossens A (1989) Identification of cross-reaction patterns in allergic contact dermatitis from topical corticosteroids. Br J Dermatol 121(1):27–34CrossRefPubMed

29.

Matura M, Goossens A (2000) Contact allergy to corticosteroids. Allergy 55(8):698–704CrossRefPubMed

30.

Lepoittevin JP, Drieghe J, Dooms-Goossens A (1995) Studies in patients with corticosteroid contact allergy. Understanding cross-reactivity among different steroids. Arch Dermatol 131(1):31–37CrossRefPubMed

31.

Wilkinson SM, English JS (1991) Hydrocortisone sensitivity: a prospective study of the value of tixocortol pivalate and hydrocortisone acetate as patch test markers. Contact Dermatitis 25(2):132–133CrossRefPubMed

32.

Lauerma AI, Tarvainen K, Forstrom L, Reitamo S (1993) Contact hypersensitivity to hydrocortisone-free-alcohol in patients with allergic patch test reactions to tixocortol pivalate. Contact Dermatitis 28(1):10–14CrossRefPubMed

33.

Jacob SE, Steele T Corticosteroid classes: a quick reference guide including patch test substances and cross-reactivity. J Am Acad Dermatol 54(4):723–727

34.

Davis MD, El-Azhary RA, Farmer SA (2007) Results of patch testing to a corticosteroid series: a retrospective review of 1188 patients during 6 years at Mayo Clinic. J Am Acad Dermatol 56(6):921–927CrossRefPubMed

35.

Gonul M, Gul U (2005) Detection of contact hypersensitivity to corticosteroids in allergic contact dermatitis patients who do not respond to topical corticosteroids. Contact Dermatitis 53(2):67–70CrossRefPubMed

36.

Baeck M, Chemelle JA, Goossens A, Nicolas JF, Terreux R (2011) Corticosteroid cross-reactivity: clinical and molecular modelling tools. Allergy 66(10):1367–1374CrossRefPubMed

37.

Baeck M, Goossens A (2012) New insights about delayed allergic hypersensitivity to corticosteroids. G Ital Dermatol Venereol 147(1):65–69PubMed

38.

Baeck M, Goossens A (2012) Immediate and delayed allergic hypersensitivity to corticosteroids: practical guidelines. Contact Dermatitis 66(1):38–45CrossRefPubMed

39.

DeKoven JG, Warshaw EM, Belsito DV et al (2017) North American contact dermatitis group patch test results 2013–2014. Dermatitis 28(1):33–46CrossRefPubMed

40.

Baeck M, Chemelle J-A, Terreux R, Drieghe J, Goossens A (2009) Delayed hypersensitivity to corticosteroids in a series of 315 patients: clinical data and patch test results. Contact Dermatitis 61(3):163–175CrossRefPubMed

41.

Kot M, Bogaczewicz J, Krecisz B, Wozniacka A (2016) Contact hypersensitivity to European baseline series and corticosteroid series Haptens in a population of adult patients with contact eczema. Acta Dermatovenerol Croat 24(1):29–36PubMed

42.

Pecquet C, Pradalier A, Dry J (1992) Allergic contact dermatitis from ethanol in a transdermal estradiol patch. Contact Dermatitis 27(4):275–276CrossRefPubMed

43.

Grebe SK, Adams JD, Feek CM (1993) Systemic sensitization to ethanol by transdermal estrogen patches. Arch Dermatol 129(3):379–380CrossRefPubMed

44.

Schwartz BK, Clendenning WE (1988) Allergic contact dermatitis from hydroxypropyl cellulose in a transdermal estradiol patch. Contact Dermatitis 18(2):106–107CrossRefPubMed

45.

Tennstedt D, Lachapelle J-M (1990) Allergic contact dermatitis from colophony in a nitroglycerin transdermal therapeutic system. Contact Dermatitis 23(4):254–255CrossRef

46.

Jordan WP Jr (1997) Allergy and topical irritation associated with transdermal testosterone administration: a comparison of scrotal and nonscrotal transdermal systems. Am J Contact Dermat 8(2):108–113PubMed

47.

Ta V, Chin WK, White AA (2014) Allergic contact dermatitis to testosterone and estrogen in transdermal therapeutic systems. Dermatitis 25(5):279CrossRefPubMed

48.

Padwick ML, Endacott J, Whitehead MI (1985) Efficacy, acceptability, and metabolic effects of transdermal estradiol in the management of postmenopausal women. Am J Obstet Gynecol 152(8):1085–1091CrossRefPubMed

49.

Corazza M, Mantovani L, Montanari A, Virgili A (2002) Allergic contact dermatitis from transdermal estradiol and systemic contact dermatitis from oral estradiol. A case report. J Reprod Med 47(6):507–509PubMed

50.

El Sayed F, Bayle-Lebey P, Marguery MC, Bazex J (1996) Systemic sensitization to 17-beta estradiol induced by transcutaneous administration. Ann Dermatol Venereol 123(1):26–28PubMed

51.

Koch P (2001) Allergic contact dermatitis from estradiol and norethisterone acetate in a transdermal hormonal patch. Contact Dermatitis 44(2):112–113CrossRefPubMed

52.

McBurney EI, Noel SB, Collins JH (1989) Contact dermatitis to transdermal estradiol system. J Am Acad Dermatol 20(3):508–510CrossRefPubMed

53.

Boehncke WH, Gall H (1996) Type-IV hypersensitivity to topical estradiol in a patient tolerant to it orally. Contact Dermatitis 35(3):187–188CrossRefPubMed

54.

Warshaw EM, Belsito DV, Taylor JS, Sasseville D, DeKoven JG, Zirwas MJ, Fransway AF, Mathias CGT, Zug KA, DeLeo VA, Fowler JF Jr, Marks JG, Pratt MD, Storrs FJ, Maibach HI (2013) North American Contact Dermatitis Group patch test results: 2009 to 2010. Dermatitis 24(2):50–59CrossRefPubMed

55.

Warshaw EM, Maibach HI, Taylor JS et al (2015) North American contact dermatitis group patch test results: 2011–2012. Dermatitis 26(1):49–59CrossRefPubMed

56.

Fransway AF, Zug KA, Belsito DV, DeLeo VA, Fowler JF Jr, Maibach HI, Marks JG, Mathias CGT, Pratt MD, Rietschel RL, Sasseville D, Storrs FJ, Taylor JS, Warshaw EM, Dekoven J, Zirwas M (2013) North American Contact Dermatitis Group patch test results for 2007–2008. Dermatitis 24(1):10–21CrossRefPubMed

57.

Pratt MD, Belsito DV, DeLeo VA, Fowler JF Jr, Fransway AF, Maibach HI, Marks JG, Mathias CG, Rietschel RL, Sasseville D, Sherertz EF, Storrs FJ, Taylor JS, Zug K (2004) North American Contact Dermatitis Group patch-test results, 2001–2002 study period. Dermatitis 15(4):176–183PubMed

58.

Warshaw EM, Belsito DV, DeLeo VA, Fowler JF Jr, Maibach HI, Marks JG, Toby Mathias CG, Pratt MD, Rietschel RL, Sasseville D, Storrs FJ, Taylor JS, Zug KA (2008) North American Contact Dermatitis Group patch-test results, 2003–2004 study period. Dermatitis 19(3):129–136PubMed

59.

Zug KA, Warshaw EM, Fowler JF Jr et al (2009) Patch-test results of the North American Contact Dermatitis Group 2005–2006. Dermatitis 20(3):149–160PubMed

60.

Thyssen JP, Engkilde K, Menne T, Johansen JD (2011) Prevalence of benzocaine and lidocaine patch test sensitivity in Denmark: temporal trends and relevance. Contact Dermatitis 65(2):76–80CrossRefPubMed

61.

Sidhu SK, Shaw S, Wilkinson JD (1999) A 10-year retrospective study on benzocaine allergy in the United Kingdom. Am J Contact Dermat. 10(2):57–61CrossRefPubMed

62.

Beck MH, Holden A (1988) Benzocaine—an unsatisfactory indicator of topical local anaesthetic sensitization for the U.K. Br J Dermatol 118(1):91–94CrossRefPubMed

63.

Gilissen L, Goossens A (2016) Frequency and trends of contact allergy to and iatrogenic contact dermatitis caused by topical drugs over a 25-year period. Contact Dermatitis 75(5):290–302CrossRefPubMed

64.

Akyol A, Boyvat A, Peksari Y, Gurgey E (2005) Contact sensitivity to standard series allergens in 1038 patients with contact dermatitis in Turkey. Contact Dermatitis 52(6):333–337CrossRefPubMed

65.

Lazarov A (2006) European Standard Series patch test results from a contact dermatitis clinic in Israel during the 7-year period from 1998 to 2004. Contact Dermatitis 55(2):73–76CrossRefPubMed

66.

Cheng S, Cao M, Zhang Y, Peng S, Dong J, Zhang D, Jiang Z, He Y (2011) Time trends of contact allergy to a modified European baseline series in Beijing between 2001 and 2006. Contact Dermatitis 65(1):22–27CrossRefPubMed

67.

Yin R, Huang XY, Zhou XF, Hao F (2011) A retrospective study of patch tests in Chongqing, China from 2004 to 2009. Contact Dermatitis 65(1):28–33CrossRefPubMed

68.

Lam WS, Chan LY, Ho SC, Chong LY, So WH, Wong TW (2008) A retrospective study of 2585 patients patch tested with the European standard series in Hong Kong (1995–99). Int J Dermatol 47(2):128–133CrossRefPubMed

69.

Boonchai W, Iamtharachai P, Sunthonpalin P (2008) Prevalence of allergic contact dermatitis in Thailand. Dermatitis 19(3):142–145PubMed

70.

Brinca A, Cabral R, Goncalo M (2013) Contact allergy to local anaesthetics-value of patch testing with a caine mix in the baseline series. Contact Dermatitis 68(3):156–162CrossRefPubMed

71.

Warshaw EM, Schram SE, Belsito DV, DeLeo V, Fowler JF Jr, Maibach HI, Marks JG Jr, Mathias CG, Pratt MD, Rietschel RL, Sasseville D, Storrs FJ, Taylor JS, Zug KA (2008) Patch-test reactions to topical anesthetics: retrospective analysis of cross-sectional data, 2001 to 2004. Dermatitis 19(2):81–85PubMed

72.

Erdmann SM, Sachs B, Merk HF (2001) Systemic contact dermatitis from cinchocaine. Contact Dermatitis 44(4):260–261CrossRefPubMed

73.

Marques C, Faria E, Machado A, Goncalo M, Goncalo S (1995) Allergic contact dermatitis and systemic contact dermatitis from cinchocaine. Contact Dermatitis 33(6):443CrossRefPubMed

74.

Yamadori Y, Oiso N, Hirao A, Kawara S, Kawada A (2009) Allergic contact dermatitis from dibucaine hydrochloride, chlorpheniramine maleate, and naphazoline hydrochloride in an over-the-counter topical antiseptic. Contact Dermatitis 61(1):52–53CrossRefPubMed

75.

LaBerge L, Pratt M, Fong B, Gavigan G (2011) A 10-year review of p-phenylenediamine allergy and related para-amino compounds at the Ottawa Patch Test Clinic. Dermatitis 22(6):332–334PubMed

76.

Vogel TA, Coenraads PJ, Bijkersma LM, Vermeulen KM, Schuttelaar ML, Group EFS (2015) p-Phenylenediamine exposure in real life—a case-control study on sensitization rate, mode and elicitation reactions in the northern Netherlands. Contact Dermatitis 72(6):355–361CrossRefPubMed

77.

Speca SJ, Boynes SG, Cuddy MA (2010) Allergic reactions to local anesthetic formulations. Dent Clin N Am 54(4):655–664CrossRefPubMed

78.

Gall H, Kaufmann R, Kalveram CM (1996) Adverse reactions to local anesthetics: analysis of 197 cases. J Allergy Clin Immunol 97(4):933–937CrossRefPubMed

79.

Jenerowicz D, Polanska A, Glinska O, Czarnecka-Operacz M, Schwartz RA (2014) Allergy to lidocaine injections: comparison of patient history with skin testing in five patients. Postepy Dermatol Alergol 31(3):134–138CrossRefPubMedPubMedCentral

80.

Gonzalez-Delgado P, Anton R, Soriano V, Zapater P, Niveiro E (2006) Cross-reactivity among amide-type local anesthetics in a case of allergy to mepivacaine. J Investig Allergol Clin Immunol 16(5):311–313PubMed

81.

Fuzier R, Lapeyre-Mestre M, Mertes PM et al (2009) Immediate- and delayed-type allergic reactions to amide local anesthetics: clinical features and skin testing. Pharmacoepidemiol Drug Saf 18(7):595–601CrossRefPubMed

82.

Ing Lorenzini K, Gay-Crosier Chabry F, Piguet C, Desmeules J (2016) Meta-xylene: identification of a new antigenic entity in hypersensitivity reactions to local anesthetics. J Allergy Clin Immunol Pract 4(1):162–164CrossRefPubMed

83.

Corbo MD, Weber E, DeKoven J (2016) Lidocaine allergy: do positive patch results restrict future use? Dermatitis 27(2):68–71CrossRefPubMed

84.

Purcell SM, Dixon SL (1985) Allergic contact dermatitis to dyclonine hydrochloride simulating extensive herpes simplex labialis. J Am Acad Dermatol 12(2 Pt 1):231–234CrossRefPubMed

85.

Maibach HI (1986) Dyclonine hydrochloride, local anaesthetic allergic contact dermatitis. Contact Dermatitis 14(2):114CrossRefPubMed

86.

Hylwa SA, Warshaw E (2014) Contact allergy to pramoxine (pramocaine): the importance of testing to personal products. Dermatitis 25(3):147–148CrossRefPubMed

87.

Cusano F, Luciano S (1993) Contact dermatitis from pramoxine. Contact Dermatitis 28(1):39CrossRefPubMed

88.

García F (2007) Contact dermatitis from prilocaine with cross-sensitivity to pramocaine and bupivacaine. Contact Dermatitis 56(2):120–121CrossRefPubMed

89.

van Ketel WG (1981) Allergy to pramoxine (pramocaine). Contact Dermatitis 7(1):49CrossRefPubMed

90.

van Ketel WG (1979) Allergy to Nestosyl ointment®. Contact Dermatitis 5(3):193–193CrossRefPubMed

91.

van Ketel WG (1983) Contact allergy to different antihaemorrhoidal anaesthetics. Contact Dermatitis 9(6):512–513CrossRefPubMed

92.

Church MK, Church DS (2013) Pharmacology of antihistamines. Indian J Dermatol 58(3):219–224CrossRefPubMedPubMedCentral

93.

Goossens A, Linsen G (1998) Contact allergy to antihistamines is not common. Contact Dermatitis 39(1):38–39CrossRefPubMed

94.

Lew BL, Haw CR, Lee MH (2004) Cutaneous drug eruption from cetirizine and hydroxyzine. J Am Acad Dermatol 50(6):953–956CrossRefPubMed

95.

Zuidema J (1985) Ethylenediamine, profile of a sensitizing excipient. Pharm Weekbl Sci 7(4):134–140CrossRefPubMed

96.

Yoshizawa A, Araki Y, Kobayashi N, Kudo K (1999) A case of aminophylline hypersensitivity reaction due to ethylenediamine. Arerugi 48(11):1206–1211PubMed

97.

Terzian CG, Simon PA (1992) Aminophylline hypersensitivity apparently due to ethylenediamine. Ann Emerg Med 21(3):312–314CrossRefPubMed

98.

de la Hoz B, Perez C, Tejedor MA, Lazaro M, Salazar F, Cuevas M (1993) Immediate adverse reaction to aminophylline. Ann Allergy 71(5):452–454PubMed

99.

Fisher AA (1976) Highlights of the first international symposium on contact dermatitis. Cutis 18(5):645–662PubMed

100.

Van Hecke E (1975) Ethylenediamine sensitivity from exposure to epoxy resin hardeners and Mycolog cream. Contact Dermatitis 1(6):344–348CrossRefPubMed

101.

Shakouri AA, Bahna SL (2013) Hypersensitivity to antihistamines. Allergy and Asthma Proceedings 34(6):488–496CrossRefPubMed

102.

Tella R, Gaig P, Bartra J, Garcia-Ortega P (2002) Urticaria to cetirizine. J Investig Allergol Clin Immunol 12(2):136–137PubMed

103.

Kranke B, Mayr-Kanhauser S (2005) Urticarial reaction to the antihistamine levocetirizine dihydrochloride. Dermatology 210(3):246–247CrossRefPubMed

104.

Sanchez Morillas L, Rojas Perez-Ezquerra P, Reano Martos M, Sanz ML, Laguna Martinez JJ (2011) Urticaria due to antihistamines. J Investig Allergol Clin Immunol 21(1):66–68PubMed

105.

Bonnel RA, La Grenade L, Karwoski CB, Beitz JG (2003) Allergic contact dermatitis from topical doxepin: Food and Drug Administration’s postmarketing surveillance experience. J Am Acad Dermatol 48(2):294–296CrossRefPubMed

106.

Taylor JS, Praditsuwan P, Handel D, Kuffner G (1996) Allergic contact dermatitis from doxepin cream. One-year patch test clinic experience. Arch Dermatol 132(5):515–518CrossRefPubMed

107.

Nethercott JR, Holness DL, Adams RM, Belsito DV, de Leo VA, Emmett EA, Fowler J, Fisher AA, Larsen W, Maibach H, Marks J, Mitchell J, Rietschel R, Rosenthal L, Schorr W, Storrs F, Taylor J (1991) Patch testing with a routine screening tray in North America, 1985 through 1989: II. Gender and response. Dermatitis 2(2):130–134CrossRef

108.

Marks JG Jr, Belsito DV, DeLeo VA et al (2000) North American Contact Dermatitis Group patch-test results, 1996–1998. Arch Dermatol 136(2):272–273CrossRefPubMed

109.

Marks JGJ, Belsito DV, DeLeo VA et al (2003) North American Contact Dermatitis Group patch-test results, 1998 to 2000. Dermatitis 14(2):59–62

110.

Forstrom L, Pirila V, Pirila L (1979) Cross-sensitivity within the neomycin group of antibiotics. Acta Derm Venereol Suppl (Stockh) 59(85):67–69

111.

Schorr WF, Wenzel FJ, Hededus SI (1973) Cross-sensitivity and aminoglycoside antibiotics. Arch Dermatol 107(4):533–539CrossRefPubMed

112.

Kimura M, Kawada A (1998) Contact sensitivity induced by neomycin with cross-sensitivity to other aminoglycoside antibiotics. Contact Dermatitis 39(3):148–150CrossRefPubMed

113.

Shi K, Caldwell SJ, Fong DH, Berghuis AM (2013) Prospects for circumventing aminoglycoside kinase mediated antibiotic resistance. Front Cell Infect Microbiol 3:22CrossRefPubMedPubMedCentral

114.

Goh CL (1986) Anaphylaxis from topical neomycin and bacitracin. Australas J Dermatol 27(3):125–126CrossRefPubMed

115.

Bommarito L, Mietta S, Cadario G (2015) Anaphylaxis after application of topical bacitracin-neomycin powder. Ann Allergy Asthma Immunol 115(1):74–75CrossRefPubMed

116.

Lin FL, Woodmansee D, Patterson R Near-fatal anaphylaxis to topical bacitracin ointment. J Allergy Clin Immunol 101(1):136–137

117.

Freiler JF, Steel KE, Hagan LL, Rathkopf MM, Roman-Gonzalez J (2005) Intraoperative anaphylaxis to bacitracin during pacemaker change and laser lead extraction. Ann Allergy Asthma Immunol 95(4):389–393CrossRefPubMed

118.

Saryan JA, Dammin TC, Bouras AE Anaphylaxis to topical bacitracin zinc ointment. Am J Emerg Med 16(5):512–513

119.

Damm S (2011) Intraoperative anaphylaxis associated with bacitracin irrigation. Am J Health Syst Pharm 68(4):323–327CrossRefPubMed

120.

Blas M, Briesacher KS, Lobato EB (2000) Bacitracin irrigation: a cause of anaphylaxis in the operating room. Anesth Analg 91(4):1027–1028 table of contentsCrossRefPubMed

121.

Parenti MA, Hatfield SM, Leyden JJ (1987) Mupirocin: a topical antibiotic with a unique structure and mechanism of action. Clin Pharm 6(10):761–770PubMed

122.

Daly BM (1987) Bactroban allergy due to polyethylene glycol. Contact Dermatitis 17(1):48–49CrossRefPubMed

123.

Eedy DJ (1995) Mupirocin allergy in the setting of venous ulceration. Contact Dermatitis 32(4):240–241CrossRefPubMed

124.

Zappi EG, Brancaccio RR (1997) Allergic contact dermatitis from mupirocin ointment. J Am Acad Dermatol 36(2 Pt 1):266CrossRefPubMed

125.

Gette MT, Marks JG Jr, Maloney ME (1992) Frequency of postoperative allergic contact dermatitis to topical antibiotics. Arch Dermatol 128(3):365–367CrossRefPubMed

126.

Bork K, Brauers J, Kresken M (1989) Efficacy and safety of 2% mupirocin ointment in the treatment of primary and secondary skin infections—an open multicentre trial. Br J Clin Pract 43(8):284–288PubMed

127.

Warshaw EM, Wang MZ, Maibach HI, Belsito DV, Zug KA, Taylor JS, Mathias CGT, Sasseville D, Zirwas MJ, Fowler JF Jr, DeKoven JG, Fransway AF, DeLeo VA, Marks JG Jr, Pratt MD, Storrs FJ (2013) Patch test reactions associated with sunscreen products and the importance of testing to an expanded series: retrospective analysis of North American Contact Dermatitis Group data, 2001 to 2010. Dermatitis 24(4):176–182CrossRefPubMed

128.

Beleznay K, de Gannes G, Kalia S (2014) Analysis of the prevalence of allergic contact dermatitis to sunscreen: a cohort study. J Cutan Med Surg 18(1):15–19CrossRefPubMed

129.

Scheuer E, Warshaw E (2006) Sunscreen allergy: a review of epidemiology, clinical characteristics, and responsible allergens. Dermatitis 17(1):3–11CrossRefPubMed

130.

de Groot AC, Veenstra M (2010) Formaldehyde-releasers in cosmetics in the USA and in Europe. Contact Dermatitis 62(4):221–224CrossRefPubMed

131.

Sasseville D (2004) Hypersensitivity to preservatives. Dermatol Ther 17(3):251–263CrossRefPubMed

132.

Rocha VB, Scherrer MA (2014) Thimerosal: current sources of contact in Brazil. An Bras Dermatol 89(2):376–378CrossRefPubMedPubMedCentral

133.

Breithaupt A, Jacob SE (2008) Thimerosal and the relevance of patch-test reactions in children. Dermatitis 19(5):275–277PubMed

134.

Freiman A, Al-Layali A, Sasseville D (2003) Patch testing with thimerosal in a Canadian center: an 11-year experience. Am J Contact Dermat 14(3):138–143PubMed

135.

Belsito DV (2002) Thimerosal: contact (non) allergen of the year. Am J Contact Dermat 13(1):1–2CrossRefPubMed

136.

Rodrigues DF, Neves DR, Pinto JM, Alves MF, Fulgencio AC (2012) Results of patch-tests from Santa Casa de Belo Horizonte Dermatology Clinic, Belo Horizonte, Brazil, from 2003 to 2010. An Bras Dermatol 87(5):800–803CrossRefPubMed

137.

Scheman A, Rakowski EM, Chou V, Chhatriwala A, Ross J, Jacob SE (2013) Balsam of Peru: past and future. Dermatitis 24(4):153–160CrossRefPubMed

138.

Larsen W, Nakayama H, Fischer T, Elsner P, Frosch P, Burrows D, Jordan W, Shaw S, Wilkinson J, Marks J Jr, Sugawara M, Nethercott M, Nethercottdagger J (1998) A study of new fragrance mixtures. Am J Contact Dermat 9(4):202–206PubMed

139.

Frosch PJ, Pirker C, Rastogi SC, Andersen KE, Bruze M, Svedman C, Goossens A, White IR, Uter W, Arnau EG, Lepoittevin JP, Menne T, Johansen JD (2005) Patch testing with a new fragrance mix detects additional patients sensitive to perfumes and missed by the current fragrance mix. Contact Dermatitis 52(4):207–215CrossRefPubMed

140.

Bruze M, Andersen KE, Goossens A (2008) Escd, Eecdrg. Recommendation to include fragrance mix 2 and hydroxyisohexyl 3-cyclohexene carboxaldehyde (Lyral) in the European baseline patch test series. Contact Dermatitis 58(3):129–133CrossRefPubMed

141.

Johansen JD (2003) Fragrance contact allergy: a clinical review. Am J Clin Dermatol 4(11):789–798CrossRefPubMed

142.

Nardelli A, Carbonez A, Drieghe J, Goossens A (2013) Results of patch testing with fragrance mix 1, fragrance mix 2, and their ingredients, and Myroxylon pereirae and colophonium, over a 21-year period. Contact Dermatitis 68(5):307–313CrossRefPubMed

143.

Engfeldt M, Hagvall L, Isaksson M et al (2017) Patch testing with hydroxyisohexyl 3-cyclohexene carboxaldehyde (HICC)—a multicentre study of the Swedish Contact Dermatitis Research Group. Contact Dermatitis 76(1):34–39CrossRefPubMed

Titel: Contact Dermatitis to Medications and Skin Products
verfasst von: Henry L. Nguyen
James A. Yiannias
Publikationsdatum: 25.08.2018
Verlag: Springer US
Erschienen in: Clinical Reviews in Allergy & Immunology / Ausgabe 1/2019
Print ISSN: 1080-0549
Elektronische ISSN: 1559-0267
DOI: https://doi.org/10.1007/s12016-018-8705-0

Neu im Fachgebiet HNO

16.04.2024 | HNO-Chirurgie | Nachrichten

Update HNO

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert – ganz bequem per eMail.

Newsletter bestellen

Live-Webinar: Aktuelle Leitlinien bei Herz-Kreislauf-Erkrankungen

Springer Medizin

Contact Dermatitis to Medications and Skin Products

Abstract

Neu im Fachgebiet HNO

HNO-Op. auch mit über 90?

Intrakapsuläre Tonsillektomie gewinnt an Boden

Bilateraler Hörsturz hat eine schlechte Prognose

„Nur wer sich gut aufgehoben fühlt, kann auch für Patientensicherheit sorgen“

Update HNO

Live-Webinar: Aktuelle Leitlinien bei Herz-Kreislauf-Erkrankungen

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 1/2019

Contact Dermatitis to Cosmetics

Occupational and Hand Dermatitis: a Practical Approach

The Unique Molecular Signatures of Contact Dermatitis and Implications for Treatment

Food-Related Contact Dermatitis, Contact Urticaria, and Atopy Patch Test with Food

Irritant Contact Dermatitis

Patch Testing Pearls

Neu im Fachgebiet HNO

HNO-Op. auch mit über 90?

Intrakapsuläre Tonsillektomie gewinnt an Boden

Bilateraler Hörsturz hat eine schlechte Prognose

„Nur wer sich gut aufgehoben fühlt, kann auch für Patientensicherheit sorgen“

Update HNO